Disruptive Growth & Healthcare Conference
New York City
The Disruptive Growth & Healthcare Conference will feature healthcare companies focusing on innovations to meet on unmet medical needs, as well as growth companies with disruptive technologies and business models. The audience is comprised of institutional investors, accredited investors, family offices, analysts, registered investment advisors, wealth managers, RHK representatives and their clients – all of whom recognize the tremendous opportunities of disruptive ideas and their infinite potential at market introduction. For more information visit www.DisruptNYC.com
Alternate Health (AHGIF)
Alternate Health (OTC: AHGIF) is a diversified healthcare company operating through a network of subsidiaries that share proprietary, highly secure cloud-based software solutions to improve efficiencies and protect patient data. The company's service offerings include practice management and controlled substance management software, blood analysis and toxicology labs, clinical research, continuing education programs, nutraceutical products, and security and control services to the emerging medical cannabis industry. The company engages the medical and medical cannabis industry with effective, legal products and services that will provide a platform for advancing patient outcomes. For more information, visit the company's website at www.alternatehealth.ca.
BioDelivery Sciences International (BDSI)
BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. The company utilizes its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology as well as other drug delivery technologies to develop and commercialize new applications of proven therapies aimed at addressing important unmet medical needs. The company also works in partnership with third parties to develop and commercialize these products. Current marketed products and products in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain and opioid dependence. BDSI's headquarters is in Raleigh, North Carolina. For more information, visit the company's website at www.bdsi.com.
Cancer Genetics (CGIX)
Cancer Genetics (NASDAQ: CGIX) develops, commercializes and provides molecular and biomarker-based tests and services in the United States, India and China. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. The company's clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management. For more information, visit the company's website at www.cancergenetics.com.
Cemtrex (NASDAQ: CETX) provides electronic manufacturing services of electric system assemblies, instruments and emission monitors for industrial processes, and industrial air filtration and environmental control systems worldwide. The industrial products & services (IPS) segment provides a range of air filtration and environmental control products to various industrial and manufacturing industries, as well as monitoring instruments, software and systems for measurement of emissions of greenhouse gases, hazardous gases, particulate, and other regulated pollutants used in emissions trading. The electronics manufacturing solutions (EMS) segment provides electronic manufacturing services, including product design and sustaining engineering services, printed circuit board assembly and production, cabling and wire harnessing, systems integration, comprehensive testing services, and assembled electronic products. For more information, visit the company's website at www.cemtrex.com.
Chanticleer Holdings (HOTR)
Chanticleer Holdings (NASDAQ: HOTR) owns, operates and franchises fast casual and full-service dining concepts in the United States and internationally. Chanticleer owns and operates and franchises restaurant brands including American Burger Company, BGR - Burgers Grilled Right, Little Big Burger, Just Fresh and Hooters. For more information, visit the company's website at www.chanticleerholdings.com.
ChineseInvestors.com (OTCQB: CIIX) is a financial information website for Chinese-speaking investors in the United States and China. The company also capitalizes on the growing demand for cannabidiol (CBD)-based nutrition and health products. CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services. For more information, visit the company's website at www.chineseinvestors.com.
CURE Pharmaceutical Holding (CURR)
CURE Pharmaceutical Holding (OTCQB: CURR) is a fully integrated specialty bioscience company. The company is focused on improving drug efficacy, safety and the patient experience with proprietary drug dosage forms and delivery systems for a broad range of molecules such as cannabinoid molecules. CURE has a full service cGMP manufacturing facility and is the developer and manufacturer of the proprietary CureFilm™ delivery system. For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com.
Dynex Capital (DX)
Dynex Capital (NYSE: DX) is an internally managed mortgage real estate investment trust (REIT) which invests in mortgage assets on a leveraged basis. The company manages a diversified, high-quality, leveraged fixed-income portfolio. Dynex invests in agency and non-agency RMBS, CMBS, and CMBS IO. The company aims to manage these assets in a way that provides its shareholders with attractive, risk-adjusted returns over the long term. For more information, visit the company's website at www.dynexcapital.com.
Generex Biotechnology (GNBT)
Generex Biotechnology (OTC: GNBT) is engaged in the research, development and commercialization of drug delivery systems and technologies. The company has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity with no deposit in the lungs. Generex's proprietary RapidMist™ device combined with its proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth. The core platform technologies of the company's wholly owned subsidiary Antigen Express, Inc. comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. For more information, visit the company's website at www.generex.com.
Heat Biologics (HTBX)
Heat Biologics (NASDAQ: HTBX) is a biopharmaceutical company developing novel therapies designed to activate a patient's immune system against cancer using its CD8+ "Killer" T-cells. The company is currently enrolling patients in its phase 2 clinical trial for non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®). The company also has numerous pre-clinical programs at various stages of development. For more information, visit the company's website at www.heatbio.com.
Imagination Park Entertainment (IPNFF)
Imagination Park Entertainment (OTC: IPNFF) is a digital content production company. The company works alongside talented filmmakers around the world in an effort to bring conventional as well as virtual reality, augmented reality, and mixed reality content to life. The company headquarters are located in Vancouver, BC, Canada with an office in Studio City, Hollywood, California. Imagination Park has recently expanded into the China market and also maintains local executive representation. For more information, visit the company's website at www.imaginationpark.com.
Immune Pharmaceuticals (IMNP)
Immune Pharmaceuticals (NASDAQ: IMNP) is focused on developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The company's lead product candidate, bertilimumab, is in phase II clinical development for moderate-to-severe ulcerative colitis as well as for bullous pemphigoid, an orphan autoimmune dermatological condition. Other indications being considered for development include atopic dermatitis, Crohn's disease, severe asthma and non-alcoholic steato-hepatitis, an inflammatory liver disease. Immune recently expanded its portfolio in immuno-dermatology with topical nano-formulated cyclosporine-A for the treatment of psoriasis and atopic dermatitis. Immune's oncology subsidiary, Cytovia, plans to develop Ceplene for maintenance remission in AML in combination with IL-2. Additional oncology pipeline products include Azixa® and crolibulin, phase 2 clinical stage vascular disrupting agents, and novel technology platforms; bispecific antibodies and NanomAbs™. Maxim Pharmaceuticals Inc., Immune's pain and neurology subsidiary, houses AmiKet™ and AmiKet™ Nano™ for the treatment of neuropathic pain. For more information, visit the company's website at www.immunepharma.com.
ITUS (NASDAQ: ITUS) is a cancer-focused biotechnology company that funds, develops, acquires and licenses emerging technologies. The company, through its subsidiary, Anixa Diagnostics Corporation, is developing a platform called Cchek™, a series of non-invasive, blood tests for the early detection of solid tumor based cancers. ITUS also frequently examines emergent technologies in related fields for further development and commercialization. For more information, visit the company's website at www.ITUScorp.com.
Jerrick Media Holdings (JMDA)
Jerrick Media Holdings (OTCQB: JMDA) is a technology company engaged in the development of digital communities, targeted marketing of branded digital content, and e-commerce opportunities algorithmically derived in relevance for each community. The company's proprietary long-form digital publishing and content distribution platform, Vocal, is capable of hosting all forms of rich media content. It uses a proprietary algorithm which intelligently bridges media-rich long-form creative content with targeted branding and ecommerce monetization opportunities in each niche-community. Additionally, each community is managed by a dedicated team, whose primary focus is on revenue conversion of the published material via digital arbitrage. For more information, visit the company's website at jerrick.media.
MagneGas (NASDAQ: MNGA) owns a patented process that converts various renewables and liquid wastes into MagneGas fuels, which can be used as an alternative to natural gas or for metal cutting. The company's tests of "MagneGas2®" metal cutting fuel validated the advantages of the cleaner, faster, more productive fuel. The company currently sells MagneGas2® into the metal working market as a replacement to acetylene. The company also sells equipment for the sterilization of bio-contaminated liquid waste for various industrial and agricultural markets. For more information, visit the company's website at www.magnegas.com.
Medical Marijuana (MJNA)
Medical Marijuana (OTC: MJNA) leverages its team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit in the cannabis and hemp industry. The company strives to create awareness within the medical marijuana industry and develop environmentally-friendly, economically sustainable businesses while increasing shareholder value. For more information, visit the company's website at www.medicalmarijuanainc.com.
Midatech Pharma (MTP)
Midatech Pharma (NASDAQ: MTP) is an international specialty pharmaceutical company focused on oncology. The company's approach comprises of developing oncology products internally and collaborating with partners in other therapy areas. The company's strategy also involves driving growth both organically and through strategic acquisitions. Midatech is currently engaged in the US commercial operation of marketing four cancer care supportive products and co-promoting two others. Additionally, the company supports its research and development activities through its two breakthrough drug delivery technologies; the company's proprietary gold nanoparticles and Q-Sphera for sustained release. For more information, visit the company's website at www.midatechpharma.com.
Oramed Pharmaceuticals (ORMP)
Oramed Pharmaceuticals (NASDAQ: ORMP) engages in the technology of oral delivery solutions for drugs currently delivered via injection. Oramed's Protein Oral Delivery (POD™) technology is based on over 30 years of research by top scientists at Jerusalem's Hadassah Medical Center. The company is focused on revolutionizing the treatment of diabetes through its proprietary flagship product, ORMD-0801, an orally ingestible insulin capsule. Oramed has completed multiple phase 2 clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. Oramed is also developing ORMD-0901, an oral GLP-1 analog capsule. For more information, visit the company's website at www.oramed.com.
Overstock.com (NASDAQ: OSTK) is an online retailer that sells a broad range of products such as furniture, décor, rugs, bedding, electronics, apparel and home improvement items. Overstock.com also offers a marketplace that provides customers access to hundreds of thousands of products from third-party sellers. Additional stores include Worldstock.com, dedicated to selling artisan-crafted products from around the world. The retail technology company is based in Salt Lake City, Utah. For more information, visit the company's website at www.overstock.com.
PotNetwork Holding (POTN)
PotNetwork Holding (OTC: POTN) is a publicly traded company that acts as a holding company for its subsidiaries, First Capital Venture Co., the owner of Diamond CBD, Inc., the maker of Diamond CBD oils. Diamond CBD focuses on the research, development, and multi-national marketing of premium hemp extracts that contain a broad range of cannabinoids and natural hemp derivatives. The company offers a robust selection of natural CBD oils and E-Liquids. For more information, visit the company's website at www.potnetworkholding.com.
Power Clouds (PWCL)
Power Clouds (OTC: PWCL) is a global renewable energy provider engaged in owning and operating clean energy power plants in multiple countries where the combination of regulatory, economic and environment elements are maximized. The company functions by operating solar parks that connect directly to national power grids rather than residential rooftops. The company's global focus results in operations that are not limited to any one geography, single commercial model or regulatory influence. For more information, visit the company's website at www.powercloudsInc.com.
Pressure BioSciences (PBIO)
Pressure BioSciences (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. The company's products are derived from the unique properties of both constant (static) and alternating (pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. The company's primary application development and sales efforts are in the biomarker discovery and forensics areas. The company also serves other areas, such as drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development, histology, and forensic applications. For more information, visit the company's website at www.pressurebiosciences.com.
PURE Bioscience (PURE)
PURE Bioscience (OTCQB: PURE) develops and commercializes proprietary antimicrobial products primarily in the food safety arena and provides solutions to pathogen and hygienic control. The company's technology platform is based on patented stabilized ionic silver, and its initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and it mitigates bacterial resistance. For more information, visit the company's website at www.purebio.com.
Reed's (NYSE: REED) develops, manufactures, markets and sells Ginger Beer, natural non-alcoholic carbonated soft drinks, Kombucha, candies and ice creams in the United States, Canada, Europe and Asia. Reed's Ginger Brews are hand brewed, not formulated and use more than a million pounds of fresh ginger combined with spices and fruit juices every year. The company's products include Reed's ginger brews, Virgil's root beer and cream sodas, Dr. Better and real cola products, such as ZERO diet sodas. The company also provides private label products, such as sparkling juices, waters and teas. For more information, visit the company's website at www.reedsinc.com.
Research Frontiers (REFR)
Research Frontiers (NASDAQ: REFR) develops and markets the technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device (SPD-Smart) light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, light-control film made from the chemical emulsion, the light-control panels made by laminating the film, lamination services, and electronics to power end-products incorporating the film, as well as the end-products, such as windows, skylights, and sunroofs. Its SPD-Smart light-control technology is used in multiple product applications. For more information, visit the company's website at www.smartglass.com.
Rexahn Pharmaceuticals (RNN)
Rexahn Pharmaceuticals (NYSE: RNN) is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for the treatment of cancer. Rexahn's product candidates target and neutralize specific proteins believed to be involved in the complex biological force that leads to cancer cell growth. The company's broad oncology pipeline includes three anti-cancer compounds currently in phase II clinical development: Supinoxin™, RX-3117, and Archexin®. Rexahn also has a novel nanopolymer-based drug delivery platform technology that may increase the bio-availability of FDA-approved chemotherapies. For more information, visit the company's website at www.rexahn.com.
Rockwell Medical (RMTI)
Rockwell Medical (NASDAQ: RMTI) is a fully-integrated biopharmaceutical company with a focus on end-stage renal disease (ESRD) and chronic kidney disease (CKD). The company provides innovative products for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. Triferic, the company's anemia drug, is FDA approved for iron replacement and maintenance of hemoglobin in hemodialysis patients. The company also has an FDA approved generic drug, Calcitriol, for treating secondary hyperparathyroidism in dialysis patients. Rockwell also manufactures high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. For more information, visit the company's website at www.rockwellmed.com.
Safeguard Scientifics (SFE)
Safeguard Scientifics (NYSE: SFE) provides capital and expertise to stimulate the growth of technology-driven businesses in healthcare, financial services and digital media. The company targets companies that are capitalizing on the next wave of enabling technologies with a particular focus on the Internet of Everything, enhanced security and predictive analytics. Safeguard typically deploys between $5 million and $25 million over the course of its partnership with a company, initially investing in a Series A or B Round and opportunistically in a Seed Round. Safeguard has a notable track record of fostering innovation and building market leaders that spans more than six decades. For more information, visit the company's website at www.safeguard.com.
VolitionRx (NYSE: VNRX) is a multi-national life sciences company engaged in the development of simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition's products are aimed to diagnose a range of cancers quickly, simply, and accurately to achieve an early diagnosis which could potentially prolong the lives of patients and improve the quality of their lives. Volition's research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide. For more information, visit the company's website at www.volitionrx.com.
Zomedica Pharmaceuticals (ZOMHF)
Zomedica Pharmaceuticals (OTC: ZOMHF) is a veterinary pharmaceutical and health care solutions company creating innovative products for companion animals (canine, feline and equine) by focusing on your needs as a clinical veterinarian. The company is developing a diversified portfolio to include diagnostics, devices, innovative drugs, and drug-delivery technologies. Zomedica's team is comprised of clinical veterinary professionals with a mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit the company's website at www.zomedica.com.